Aim: ABO-incompatible (ABOi) kidney transplantation overcomes immunological barrier of blood group incompatibility. There have been very few published experiences of ABOi kidney transplantation from India. We present our single-center experience of the first hundred ABOi kidney transplants.
Material And Methods: This is a single-center retrospective study of consecutive first hundred ABOi kidney transplant with at least 6 months of follow-up.
Results: During the study period (2011-2020), a total of 121 ABOi kidney transplants were performed. Of these, first hundred patients were analyzed. Median follow-up duration was 33 (10-101) months. Mean recipient and donor age were 41.5 ± 13 and 47.68 ± 11.25 years, respectively. Mean HLA mismatch was 4 ± 1.5. Median baseline anti-blood group antibody titer was 128 (2-1024). Most common recipient blood group was O. Patient and death censored graft survival was 93% and 94%, respectively, at median follow-up of 33 months. Biopsy-proven acute rejection (BPAR) rate was 17% with acute antibody-mediated rejection being 3%. Rate of infection was 37%, most common being urinary tract infection.
Conclusion: ABOi kidney transplant patients had acceptable patient and graft survival as well as BPAR rates. With current preconditioning protocol, infection rate was high.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8916160 | PMC |
| http://dx.doi.org/10.4103/ijn.IJN_465_20 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of ABO-incompatible kidney transplants with very high isoagglutinin titers: a single-center experience and literature review.
Front Immunol
December 2024
Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble University Hospital, Grenoble, France.
Background: ABO-incompatible kidney transplantation (ABOi-KTx) represents a possible solution to address the shortage of kidney donors. However, these transplants present immunological challenges, particularly when isoagglutinin titers are elevated pretransplant.
Methods: Single-center retrospective study describing clinical and biological outcomes of 8 patients who underwent ABOi-KTx with initial isoagglutinin titers ≥ 1/512.
The Burden of ABO-Incompatible Kidney Transplantation: Readmission Rates and Complications, a Twenty-Year Analysis.
J Clin Med
December 2024
Department of Visceral Surgery and Transplantation, University Hospital Zurich, 8091 Zurich, Switzerland.
: ABO-incompatible live-donor kidney transplantation (ABOi-LDKT) has become an established treatment for end-stage renal disease. Non-inferiority in the long-term graft function compared to ABO-compatible live-donor kidney transplantations (ABOc-LDKTs) has been shown. However, the assumed burden due to complications owing to increased immunosuppression inherent to ABOi-LDKTs has not yet been quantified.
View Article and Find Full Text PDFA comparative study on outcomes of ABO-incompatible kidney transplants between robot-assisted vs. open surgery-propensity score-matched analysis: a retrospective cohort study.
BMC Nephrol
November 2024
Division of Kidney and Pancreas Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea.
Article Synopsis
- Robot-assisted kidney transplantation (RAKT) is gaining popularity, but there's limited research on its effectiveness for immunologically high-risk patients, particularly those with ABO incompatibility (ABOi), compared to traditional open kidney transplantation (OKT).
- A study involving 239 living-donor transplants compared 210 ABOi-OKT cases with 29 ABOi-RAKT cases, using statistical methods to ensure valid comparisons and analyze outcomes like acute rejection and graft failure.
- Results showed similar one- and two-year survival rates and kidney function between RAKT and OKT, but RAKT had longer surgery times and cold ischemic periods, while hospital stays were shorter for RAKT, indicating it is a safe and effective
Successful eculizumab treatment as an adjunctive therapy to desensitization in ABO-incompatible living donor kidney transplantation and its molecular phenotypes.
Front Immunol
November 2024
Department of Internal Medicine, College of Medicine, Yonsei University, Seoul, Republic of Korea.
Article Synopsis
- ABO-incompatible kidney transplantation (KT) is increasingly used to address organ shortages, but high levels of anti-ABO antibodies can hinder successful transplantation despite existing desensitization methods.
- Eculizumab was used as an additional treatment to help patients with very high anti-ABO antibodies who did not respond to standard therapies, showing improvements in kidney function and antibody levels after transplant.
- The study indicates that short-term eculizumab treatment may effectively support ABOi KT patients by maintaining stable kidney function and reducing antibody levels, even in cases previously deemed challenging.
C1q Binding Ability for Prior Risk Assessment of Acute Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.
Transpl Int
October 2024
Department of Renal Transplant Surgery, Aichi Medical University School of Medicine, Nagakute, Japan.
Article Synopsis
- The study investigates the risk factors for acute antibody-mediated rejection (ABMR) in ABO blood group incompatible kidney transplants (ABO-I), focusing on donor and recipient samples.
- Researchers analyzed A/B antigen expression in kidney tissues and other blood components from 104 donors and assessed pre-transplant recipient serum samples for antibody levels.
- They found that while A/B antigen levels in donors did not correlate with ABMR incidence, higher C1q-IgG binding ability in recipients was linked to an increased risk of ABMR, suggesting it may serve as a predictive indicator.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!